INmune Bio presents MINDFuL Phase II baseline data at AD/PD 2025; topline results due June 2025

Inmune Bio, Inc.

Poster details baseline demographics of 208 patients (44% MCI, 56% mild AD) enrolled in MINDFuL Phase II trial of XPro1595.
69.2% of patients are APOE ε4 carriers; 64.4% met inclusion criteria for more than one inflammation biomarker.
Primary endpoint is change from baseline in Early and Mild Alzheimer's Cognitive Composite (EMACC) score; topline results expected June 2025.
Patients randomized 2:1 to XPro 1.0 mg/kg or placebo once weekly for 23 weeks; screen failure rate was 72%.
Baseline characteristics show similarity to Phase III trials; no efficacy data disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.